Results 61 to 70 of about 4,828 (174)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria (Versão em Português), 2017
Objective: This study aims to describe real world palivizumab use and effectiveness in high‐risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source

Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region

Oman Medical Journal
Respiratory syncytial virus (RSV) infection poses a significant health threat to infants and young children. Considering the substantial burden in Gulf Cooperation Council (GCC) countries, prevention of RSV remains a major public health priority ...
Adel S. Alharbi, Abdul Rahman Alnemri, Ahmed Abushahin, Entesar Alhammadi, Huda Sulaiman Mohammed AlDhanhani, Laila Obaid , Mahmoud Saleh ElHalik, Mariam Kh Ayed   +7 more
doaj   +1 more source

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

BMC Infectious Diseases
Aim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection.
Jaime E. Ordóñez, Victor M. Huertas
doaj   +1 more source

Economic disadvantages of palivizumab [PDF]

Archives of Disease in Childhood, 2000
Editor,—We would fully agree with Dr Sanjeev Deshpande's appraisal of the economic disadvantages of palivizumab ( Arch Dis Child 2000; 82 :88–90) and …
openaire   +1 more source

Respiratory syncytial virus immunization patterns in Germany, 2015–2020

Human Vaccines & Immunotherapeutics
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated
Moritz Wick, Roman Kliemt, Anahita Poshtiban, Nils Kossack, Gerhard-Paul Diller, Samira Soudani, Mathieu Bangert, Rolf Kramer, Oliver Damm   +8 more
doaj   +1 more source

GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA

Zdravniški Vestnik, 2002
Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children under 12 months of age. Premature children and those with chronic lung disease are at increased risk for severe RSV infection.
Marko Pokorn, Milan Čižman, Janez Primožič, Janez Babnik, Silvo Kopriva, Zdravko Roškar   +5 more
doaj  

Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group

Pediatric Health, Medicine and Therapeutics, 2014
Gerard Notario,1 Pamela Vo,2 Katherine Gooch,2 Roger Deaton,3 Xionghua Wu,4 Brian Harris,4 Parthiv J Mahadevia,4 Pablo J Sánchez51Clinical Development and Medical Affairs, 2Global Heath Economics and Outcomes Research, 3Statistics, AbbVie Inc ...
Notario G, Vo P, Gooch K, Deaton R, Wu X, Harris B, Mahadevia PJ, Sánchez PJ   +7 more
doaj  

Palivizumab em contexto domiciliário

, 2012
O Departamento de Pediatria, nomeadamente a UCIENP, através do Projeto de Apoio Domiciliário ao Recém-Nascido internado na UCIEN, formou em 2009, uma equipa multidisciplinar de apoio domiciliário, em parceria com a Fundação do Gil, procurando contribuir para a melhoria na qualidade de vida da criança e sua família.
Cunha, A, Amaral, J, Costa, M, Lopez, M
openaire   +2 more sources

DISTRIBUTION PROFILE OF PALIVIZUMAB IN BRAZIL: ANALYSIS OF REGIONAL DISTRIBUTION BETWEEN 2014 AND 2024 FOR PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN CHILDREN CARED FOR BY THE UNIFIED HEALTH SYSTEM (SUS)

Brazilian Journal of Infectious Diseases
Introduction/Objectives: Palivizumab is recommended to prevent severe RSV infections in children at higher risk, such as preterm infants (gestational age ≤28 weeks) and children under 2 years of age with chronic lung disease or congenital heart disease ...
Jônatas Cunha Barbosa Lima, Daniel Moreira Alves da Silva, Luciana de Vasconcelos Rebouças, Kllysmann Santos Ribeiro, Thamela Cristiny Simão Alves, Vanessa Cristina Ribeiro, Matheus Malveira Vaz, Rodrigo Ramos Sena, Nara Amanda Laismann, Ana Liani Beisl Oliveira, Rafaela Tavares Peixoto, Luiz Henrique Costa, Marco Aurelio Pereira   +12 more
doaj   +1 more source

One-year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America

Jornal de Pediatria
Objective: This study aims to describe real world palivizumab use and effectiveness in high-risk Latin American infants and young children. Method: Prospective, multicenter observational study with infants at risk for severe RSV infection who received ...
Leandro Martin Castillo, Gabriela Bugarin, Juan Carlos Arias, Jairo Israel Barajas Rangel, Maria Elina Serra, Nestor Vain   +5 more
doaj   +1 more source